NEOCAL 300
NEOCAL 300
Authorised
- Calcium gluconate
- CALCIUM GLYCEROPHOSPHATE
- Magnesium chloride hexahydrate
- Caffeine
Product identification
Medicine name:
НЕОКАЛ 300
NEOCAL 300
Active substance:
- Calcium gluconate
- CALCIUM GLYCEROPHOSPHATE
- Magnesium chloride hexahydrate
- Caffeine
Target species:
-
Horse
-
Cattle
-
Sheep
-
Goat
-
Pig
-
Dog
-
Cat
Route of administration:
-
Intravenous use
-
Subcutaneous use
Product details
Active substance and strength:
-
Calcium gluconate160.00milligram(s)1.00millilitre(s)
-
CALCIUM GLYCEROPHOSPHATE66.00milligram(s)1.00millilitre(s)
-
Magnesium chloride hexahydrate64.00milligram(s)1.00millilitre(s)
-
Caffeine20.00milligram(s)1.00millilitre(s)
Pharmaceutical form:
-
Solution for injection
Withdrawal period by route of administration:
-
Intravenous use
-
Horse
-
Cattle
-
Sheep
-
Goat
-
Pig
-
Dog
-
Cat
-
-
Subcutaneous use
-
Horse
-
Meat and offal0dayМляко: нула дни.
-
-
Cattle
-
Meat and offal0dayМляко: нула дни.
-
-
Sheep
-
Meat and offal0dayМляко: нула дни.
-
-
Goat
-
Meat and offal0dayМляко: нула дни.
-
-
Pig
-
Meat and offal0day
-
-
Dog
-
Cat
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QA12AX
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Bulgaria
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Well-established use application (Article 13a of Directive No 2001/82/EC)
Marketing authorisation holder:
- Dsm Denitrans OOD
Marketing authorisation date:
Manufacturing sites for batch release:
- Dsm Denitrans OOD
Responsible authority:
- Bulgarian Food Safety Authority
Authorisation number:
- 0022-2872
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
Bulgarian (PDF)
Published on: 17/01/2023
How useful was this page?: